AVAX Technologies Inc.

Henry E. Schea III has been the Director of Quality Systems for AVAX since May 2002. Mr. Schea has over 20 years experience in research, product development, GMP manufacturing and quality control and assurance, with a focus in cell and gene therapies. From 1981 to 1991, Mr. Schea served in various manufacturing and quality control positions at Amgen. From 1991 through 2001, Mr. Schea developed quality systems for new biotech firms including Gene Medicine and Chimeric Therapies. Mr. Schea received his B.S. in Microbial Genetics from the University of Massachusetts in 1976.

Andres Crespo joined the Company as General Manager of its Genopoietic subsidiary when it was acquired by the Company in 2000. Prior to joining Genopoietic, Dr. Crespo was in charge of biopharmaceutical production for Rhone-Poulenc and later Rhone-Poulenc's Gencell division, where he was responsible for organizing the coordination of the various Rhone-Poulenc laboratories specializing in gene therapy. Dr. Crespo was also in charge of the GMP production of gene therapy vectors while at Rhone-Poulenc. Dr. Crespo received his M.Sc. and Ph.D. from the University of Toulouse in Pharmaceutical Sciences.

John Prendergast, Executive Chairman and CEO, is a biopharmaceutical executive who has been involved in the financing and corporate development of early to mid-stage biotechnology companies over the past 15 years. He is a co-inventor of Antyra's Phenogenix and Proteome Panning? technology modules. He is a co-founder and currently serves on the boards of Avigen Inc., Palatin Technologies and Avax Technologies. From 1991-1996, Dr. Prendergast was Managing Director of the Castle Group, a New York-based merchant bank where he was responsible for the identification and evaluation of products and technologies for the formation and development of a range of venture start-ups. He is currently the President of SummerCloud Bay Inc., a consulting practice specializing in these activities.

r. Spana, co-founder of Palatin, has been our chief executive officer and president since June 14, 2000. He has been a director of Palatin since June 1996 and has been a director of our wholly-owned subsidiary, RhoMed Incorporated, since July 1995. From June 1996 through June 14, 2000, Dr. Spana served as an executive vice president and our chief technical officer. From June 1993 to June 1996, Dr. Spana was vice president of Paramount Capital Investments, LLC, a biotechnology and biopharmaceutical merchant banking firm, and of The Castle Group Ltd., a medical venture capital firm. Through his work at Paramount Capital Investments and The Castle Group, Dr. Spana co-founded and acquired several private biotechnology firms. From July 1991 to June 1993, Dr. Spana was a Research Associate at Bristol-Myers Squibb, a publicly traded pharmaceutical company, where he was involved in scientific research in the field of immunology. Dr. Spana is a director of AVAX Technologies, Inc., a publicly-held life science company. Dr. Spana received his Ph.D. in molecular biology from The Johns Hopkins University and his B.S. in biochemistry from Rutgers University.